Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers
Emerging Company Profile: Chengdu-based ACB joins a growing wave of next-gen synthetic lethality companies
With an initial focus on MYC-driven cancers, Anticancer Bioscience joins a growing wave of next-generation synthetic lethality companies looking beyond the DNA damage response pathway kinases that have dominated the space.
President and CEO Dun Yang launched Anticancer Bioscience Ltd. (ACB) in 2016 to develop and commercialize research out of the J. Michael Bishop Institute of Cancer Research in Chengdu, which he directs. Yang completed his postdoc at the University of California San Francisco under Bishop, a Nobel Laureate whose group discovered and was first to clone MYC...